<DOC>
	<DOCNO>NCT00421122</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety Symbicort® Turbuhaler® Chinese COPD patient define GOLD treatment guideline order obtain approval indication COPD Chinese State Food Drug Administration .</brief_summary>
	<brief_title>Efficacy Safety Study Symbicort Turbuhaler Chinese Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Signed dated inform consent Outpatient , clinical diagnosis COPD Men woman age 40 A history asthma Seasonal allergic rhinitis 40 year age Patients significant unstable ischemic heart disease , arrhythmia , cardiomyopathy , heart failure , uncontrolled hypertension define investigator disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Chinese patient</keyword>
	<keyword>COPD</keyword>
</DOC>